These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37660770)

  • 1. Real-World Efficacy of Dupilumab in Severe, Treatment-Refractory, and Fibrostenotic Patients With Eosinophilic Esophagitis.
    Lee CJ; Dellon ES
    Clin Gastroenterol Hepatol; 2024 Feb; 22(2):252-258. PubMed ID: 37660770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
    Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
    Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab in adolescent eosinophilic esophagitis: Experience with fibrostenosis and eosinophilic gastrointestinal disease with esophageal involvement.
    Becker R; Rigsby M; Suchi M; Lerner DG; Chugh A
    J Pediatr Gastroenterol Nutr; 2024 Jun; 78(6):1337-1341. PubMed ID: 38587127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use.
    Spergel BL; Ruffner MA; Godwin BC; Liacouras CA; Cianferoni A; Gober L; Hill DA; Brown-Whitehorn TF; Chaiboonma K; Aceves SA; Muir AM; Spergel JM
    Ann Allergy Asthma Immunol; 2022 May; 128(5):589-593. PubMed ID: 35085819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of dupilumab in the treatment of eosinophilic esophagitis.
    Syverson EP; Rubinstein E; Lee JJ; McDonald DR; Hait E
    Immunotherapy; 2024; 16(13):845-852. PubMed ID: 39073081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world efficacy of dupilumab in four cases of paediatric-onset fibrostenotic eosinophilic esophagitis.
    Patel SA
    Clin Exp Pharmacol Physiol; 2024 Aug; 51(8):e13903. PubMed ID: 38889994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cell-Fibroblast Crosstalk.
    Shoda T; Wen T; Caldwell JM; Ben-Baruch Morgenstern N; Osswald GA; Rochman M; Mack LE; Felton JM; Abonia JP; Arva NC; Atkins D; Bonis PA; Capocelli KE; Collins MH; Dellon ES; Falk GW; Gonsalves N; Gupta SK; Hirano I; Leung J; Menard-Katcher PA; Mukkada VA; Putnam PE; Rudman Spergel AK; Spergel JM; Wechsler JB; Yang GY; Aceves SS; Furuta GT; Rothenberg ME;
    Gastroenterology; 2022 Feb; 162(2):439-453. PubMed ID: 34687736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study.
    Bredenoord AJ; Dellon ES; Hirano I; Lucendo AJ; Schlag C; Sun X; Glotfelty L; Mannent L; Maloney J; Laws E; Mortensen E; Shabbir A
    Gut; 2024 Feb; 73(3):398-406. PubMed ID: 38050037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.
    Chehade M; Dellon ES; Spergel JM; Collins MH; Rothenberg ME; Pesek RD; Hirano I; Liu R; Laws E; Mortensen E; Martincova R; Shabbir A; McCann E; Kamal MA; Kosloski MP; Hamilton JD; Samuely C; Lim WK; Wipperman MF; Farrell A; Patel N; Yancopoulos GD; Glotfelty L; Maloney J
    N Engl J Med; 2024 Jun; 390(24):2239-2251. PubMed ID: 38924731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory Pediatric Fibrostenotic Eosinophilic Esophagitis Treated With Dupilumab.
    Gangadharan Nambiar G; Rahhal R; Davis BP; Xiong Y; Cheung D
    ACG Case Rep J; 2022 Nov; 9(11):e00887. PubMed ID: 36382335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center.
    Syverson EP; Rubinstein E
    JPGN Rep; 2022 May; 3(2):e180. PubMed ID: 37168913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice.
    Laserna-Mendieta EJ; Casabona S; Savarino E; Perelló A; Pérez-Martínez I; Guagnozzi D; Barrio J; Guardiola A; Asensio T; de la Riva S; Ruiz-Ponce M; Rodríguez-Oballe JA; Santander C; Arias Á; Lucendo AJ;
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2903-2911.e4. PubMed ID: 31988045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Esophageal Dilation in Eosinophilic Esophagitis: Safety, Efficacy, and Persistence of the Fibrostenotic Phenotype.
    Runge TM; Eluri S; Cotton CC; Burk CM; Woosley JT; Shaheen NJ; Dellon ES
    Am J Gastroenterol; 2016 Feb; 111(2):206-13. PubMed ID: 26753894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Worsened Fibrostenotic Outcomes in Eosinophilic Esophagitis Patients Due to COVID-19-Related Endoscopy Cancellations.
    Ocampo AA; Dellon ES
    Dig Dis Sci; 2023 Feb; 68(2):396-403. PubMed ID: 35790699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
    Hirano I; Collins MH; Assouline-Dayan Y; Evans L; Gupta S; Schoepfer AM; Straumann A; Safroneeva E; Grimm M; Smith H; Tompkins CA; Woo A; Peach R; Frohna P; Gujrathi S; Penenberg DN; Li C; Opiteck GJ; Olson A; Aranda R; Rothenberg ME; Dellon ES;
    Gastroenterology; 2019 Feb; 156(3):592-603.e10. PubMed ID: 30395812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab Can Induce Remission of Eosinophilic Gastritis and Duodenitis: A Retrospective Case Series.
    Sia T; Bacchus L; Tanaka R; Khuda R; Mallik S; Leung J
    Clin Transl Gastroenterol; 2024 Jan; 15(1):e00646. PubMed ID: 37753954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esophageal Distensibility Defines Fibrostenotic Severity in Pediatric Eosinophilic Esophagitis.
    Hoffmann NV; Keeley K; Wechsler JB
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1188-1197.e4. PubMed ID: 36122653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrabolus pressure on high-resolution manometry distinguishes fibrostenotic and inflammatory phenotypes of eosinophilic esophagitis.
    Colizzo JM; Clayton SB; Richter JE
    Dis Esophagus; 2016 Aug; 29(6):551-7. PubMed ID: 25913144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing Eosinophil Counts in Eosinophilic Esophagitis in Children Is Associated With Reduction in Later Stricture Development.
    Strauss Starling A; Ren Y; Li H; Spergel JM; Muir AB; Lynch KL; Liacouras CA; Falk GW
    Am J Gastroenterol; 2024 Oct; 119(10):2002-2009. PubMed ID: 38661151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Rothenberg ME; Dellon ES; Collins MH; Hirano I; Chehade M; Bredenoord AJ; Lucendo AJ; Spergel JM; Sun X; Hamilton JD; Mortensen E; Laws E; Maloney J; Mannent LP; McCann E; Liu X; Glotfelty L; Shabbir A
    Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):990-1004. PubMed ID: 37660704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.